MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$2,306,339
EPS
-$0.05
Unit: Dollar
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development (including 1,375,000, 4,625,000, 2,750,000 and 6,000,000 from a related party for the three months ended june 30, 2026 and 2025 and the six months ended june 30, 2026 and 2025, respectively)
1,400,232
1,400,275
-2,969,594.5*
4,152,642
General and administrative (including 63,231, 65,151, 133,177 and 129,586 from related parties for the three months ended june 30, 2026 and 2025 and the six months ended june 30, 2026 and 2025, respectively)
684,015
891,789
515,778*
648,507
Total operating expenses
2,084,247
2,292,064
-2,453,816.5
4,801,149
Gain from operations
-2,084,247
-2,292,064
2,453,816.5
-4,801,149
Change in fair value of derivative liabilities
222,092
-
-
-
Total other expenses
-222,092
-
-
-
Gain before income tax
-2,306,339
-2,292,064
2,453,816.5*
-4,801,149
Income tax provision
-
-
-1,712*
-
Net gain
-2,306,339
-2,292,064
2,455,528.5
-4,801,149
Basic EPS
-0.05
-0.05
0.066
-0.13
Diluted EPS
-0.05
-0.05
0.066
-0.13
Basic Average Shares
42,997,733
42,121,075
37,200,817
37,096,024
Diluted Average Shares
42,997,733
42,121,075
37,200,817
37,096,024
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net gain-$2,306,339 (58.41%↑ Y/Y)Gain before incometax-$2,306,339 (58.40%↑ Y/Y)Gain from operations-$2,084,247 (62.41%↑ Y/Y)Total other expenses-$222,092 Total operatingexpenses$2,084,247 (-62.41%↓ Y/Y)Change in fair value ofderivative liabilities$222,092 Research and development(including 1,375,000,...$1,400,232 (-69.95%↓ Y/Y)General andadministrative (including...$684,015 (-22.60%↓ Y/Y)

Estrella Immunopharma, Inc. (ESLA)

Estrella Immunopharma, Inc. (ESLA)